Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF) (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $666000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 8.47% to $666000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 6.83% increase, with the full-year FY2025 number at $2.6 million, up 6.83% from a year prior.
  • Depreciation & Amortization (CF) was $666000.0 for Q4 2025 at Artiva Biotherapeutics, up from $662000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $666000.0 in Q4 2025 to a low of $500000.0 in Q2 2023.
  • A 3-year average of $607090.9 and a median of $614000.0 in 2024 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 20.6% in 2024; the steepest drop was 3.37% in 2024.
  • Artiva Biotherapeutics' Depreciation & Amortization (CF) stood at $594000.0 in 2023, then grew by 3.37% to $614000.0 in 2024, then grew by 8.47% to $666000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Depreciation & Amortization (CF) are $666000.0 (Q4 2025), $662000.0 (Q3 2025), and $641000.0 (Q2 2025).